Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 10 March 2021

Situation Report No. 245 - Kingdom of Bahrain

11th of March, 2021

World Health Organization

	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	117,332,262	2,605,356	6,720,130	148,525
New	774,877 in 2 days	14,296 in 2 days	69,914 in 2 days	819 in 2 days

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	128,428	121,776	476	6,176	58	3,242,520
New	1,173 in 2 days	1,287 in 2 days	3 in 2 days	-	-	32,335 in 2 days

HIGHLIGHTS

- The Mortality were: 3 Bahraini citizens [1 male (70 years old) and 2 female (68 and 74 years old)].
- Increasing number of citizens and residents continue to take COVID-19 Vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 10 March 2021 for the first dose (311,829) and for the second dose (206,072).
- Ministry of Health (MOH) Undersecretary praised competence and dedication of the Bahraini health workers in confronting the Coronavirus pandemic.
- MOH Undersecretary indicated that priority in recruitment is given to the Bahraini volunteer health workers based on vacancies corresponding to their qualifications.
- Public Security Assistant Chief stressed individual responsibility in combating COVID-19, urging compliance with mandatory precautionary measures.
- Last month recorded the highest COVID-19 deaths ever since the onset of the pandemic in Bahrain.
- A study revealed that COVID-19 carriers in Bahrain who are asymptomatic are the 'silent spreaders' transmitting the virus at a high rate.
- Over 80 government services have migrated to online last year due to the COVID-19 pandemic.
- A Restaurant Manager stands a trial for breaking COVID-19 rules and precautionary measure for the third time.
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies; see link below.
- WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of denguesero surveys; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO :Emergency Global Supply Chain System(COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmun oassay; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: interim guidance Operational considerations for COVID19 surveillance using GISRS; see link below.
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic; see link below.
- WHO: As COVID19 spread accelerates ,IHR Emergency Committee urges focus on measures that work; see link below.
- WHO: The push for aCOVID-19 vaccine; see link below.
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO Living Guideline: The rapeutics andCOVID-19; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca; see link below.
- WHO: Rotavirus vaccines made available for use in humanitarian crises; see link below.
- WHO: COVID-19 Virtual Press conference transcript; see link below.
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines; see link below.







IMPORTANT LINKS

- **Daily COVID-19 updates on MoH website:** https://www.moh.gov.bh/
- **WHO's COVID-19 weekly situation reports:** https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200817-weekly-epi-update 1.pdf?sfvrsn=b6d49a76_4
- **WHO's COVID-19 Dashboard:** https://covid19.who.int/
- **WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies:** https://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies
- **WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of denguesero surveys:** https://www.who.int/publications/i/item/978-92-4-151258-9
- **WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic :** https://bit.ly/2Svds0r
- **WHO :Emergency Global Supply Chain System(COVID-19) catalogue:** https://www.who.int/publications/i/item/emergency-global-supply-chain-system-(covid-19)-catalogue
- **WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmun oassays** :bit.ly/2IFOjVF
- **WHO: Global TB progress a trisk** :https://bit.ly/34dtx1H
- **WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination** :bit.ly/2JOwxWQ
- **WHO: interim guidance Operational considerations for COVID19 surveillance using GISRS:** https://bit.ly/34APNSG
- **WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic:** bit.ly/31OSjDF
- **WHO: As COVID19 spread accelerates ,IHR Emergency Committee urges focus on measures that work :** https://bit.ly/37ZI0I6
- **WHO: Thepush for aCOVID-19 vaccine** :https://bit.ly/3mS3hAa
- **WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines:** bit.ly/3panKSM
- **WHO Living Guideline: The rapeutics andCOVID-19:** https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline
- **WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19:** https://www.who.int/publications/i/item/WHO-2019-nCoV-HCF_assessment-Products-2020.1
- **WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector:** https://www.who.int/publications/i/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector
- **WHO: Health workforce policy and management in the context of the COVID-19 pandemic response:** file:///C:/Users/aldeird/Downloads/WHO-2019-nCoV-health_workforce-2020.1-eng.pdf
- **WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises:** https://www.who.int/publications/i/item/9789240017467
- **COVID-19 vaccine introduction and deployment costing tool:** https://www.who.int/publications/i/item/10665337553
- **WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19placebo-controlled vaccine trials and trial unblinding:** https://www.who.int/publications/i/item/WHO-2019-nCoV-Policy_Brief-EUD_placebo-controlled_vaccine_trials-2020.1
- **WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19:** https://www.who.int/publications/i/item/WHO-2019-nCoV-Risk-based-international-travel-2020.1
- **WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19:** https://www.who.int/publications/i/item/WHO-2019-nCoV-Risk-based_international_travel-Assessment_tool-2020.1
- **WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021:** https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021
- **WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages:** https://www.who.int/publications/i/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages
- **WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access:** https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access
- **Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca:** https://www.who.int/publications/i/item/background-document-on-the-azd1222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazeneca
- **WHO: Rotavirus vaccines made available for use in humanitarian crises:** https://www.who.int/news/item/04-03-2021-rotavirus-vaccines-made-available-for-use-in-humanitarian-crises
- **WHO: COVID-19 Virtual Press conference transcript:** https://www.who.int/publications/m/item/covid-19-virtual-press-conference-transcript---8-march-2021
- **WHO: Draft landscape and tracker of COVID-19 candidate vaccines:** https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

IMPORTANT CONTACTS

- **The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAli5@health.gov.bh**
- **International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh**